Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
OBJECTIVE
evaluation of a self-injection program with a mixture of papaverine, phentolamine and prostaglandin E1 (PGE1).


METHODS
a self-injection program for erectile dysfunction was started by 48 patients, using a 1-ml mixture of 4.5 mg papaverine, 0.2 mg phentolamine and 1.5 micrograms PGE1. Patients completed a questionnaire at 6 weeks and at 3 months and were followed at the Outpatients Department for an average of 1 year.


RESULTS
of these patients 25 had previous experience with 20 micrograms PGE1 for intracavernous use and 22 patients had previously used 30 mg papaverine with 1 mg phentolamine. None of these 3 self-injection drugs is obviously superior in its ability to induce erections. Priapism occurred twice on a total of 1,290 injections. After 1-year follow-up, 4 patients had developed problems with fibrosis of the corpora, 2 of whom had encountered this problem also in a previous self-injection program.


CONCLUSIONS
this triple mixture has the disadvantage of causing fibrosis and priapism in susceptible patients.
Meinhardt
W
W
Department of Urology, University Hospital of Leiden, The Netherlands.
Lycklama à Nijeholt
A A
AA
Kropman
R F
RF
Vermeij
P
P
Zwartendijk
J
J
D000527:Alprostadil / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005355:Fibrosis / Q000139:chemically induced; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D010208:Papaverine / Q000008:administration & dosage* / Q000009:adverse effects; D010410:Penile Erection / Q000187:drug effects; D010413:Penis / Q000473:pathology; D010646:Phentolamine / Q000008:administration & dosage* / Q000009:adverse effects; D011317:Priapism / Q000139:chemically induced; D012646:Self Administration
D004338:Drug Combinations; D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine